Items where authors include "Bullement, A."

Article

Bullement, A. orcid.org/0000-0001-7091-0972, Edmondson-Jones, M., Guyot, P. et al. (4 more authors) (2024) MPES-R: multi-parameter evidence synthesis in R for survival extrapolation—a tutorial. PharmacoEconomics, 42 (12). pp. 1317-1327. ISSN 1170-7690

Bullement, A., Edmondson-Jones, M. and Latimer, N. (2024) Cost-effectiveness of first-line immunotherapy combinations with or without chemotherapy for advanced non-small cell lung cancer: a modelling approach. BMC Cancer, 24 (1). 879. ISSN 1471-2407

Vadgama, S. orcid.org/0000-0002-9138-8471, Pasquini, M.C. orcid.org/0000-0003-1579-2293, Maziarz, R.T. orcid.org/0000-0002-8184-7099 et al. (7 more authors) (2024) “Don't keep me waiting”: estimating the impact of reduced vein-to-vein time on lifetime US 3L+ LBCL patient outcomes. Blood Advances, 8 (13). pp. 3519-3527. ISSN 2473-9529

Gal, P., Feldmajer, G., Augusto, M. orcid.org/0000-0002-2010-8284 et al. (5 more authors) (2023) De novo cost-effectiveness model framework for nonalcoholic steatohepatitis—modeling approach and validation. PharmacoEconomics, 41 (12). pp. 1629-1639. ISSN 1170-7690

Bullement, A. orcid.org/0000-0001-7091-0972, Stevenson, M.D., Baio, G. et al. (2 more authors) (2023) A systematic review of methods to incorporate external evidence into trial-based survival extrapolations for health technology assessment. Medical Decision Making, 43 (5). pp. 610-620. ISSN 0272-989X

Hamerton, L., Gomes, K., Fougeray, R. et al. (4 more authors) (2023) A UK cost–effectiveness analysis of trifluridine/tipiracil for heavily pretreated metastatic gastroesophageal cancers. Future Oncology, 19 (9). pp. 643-650. ISSN 1479-6694

Critchlow, S. orcid.org/0000-0001-6862-765X, Bullement, A. orcid.org/0000-0001-7091-0972, Crabb, S. orcid.org/0000-0003-3521-9064 et al. (9 more authors) (2023) Cost–effectiveness analysis for avelumab first-line maintenance treatment of advanced urothelial carcinoma in Scotland. Future Oncology, 20 (8). pp. 459-470. ISSN 1479-6694

Bullement, A. orcid.org/0000-0001-7091-0972 and Kearns, B. orcid.org/0000-0001-7730-668X (2022) Incorporating external trial data to improve survival extrapolations: a pilot study of the COU-AA-301 trial. Health Services and Outcomes Research Methodology, 22. pp. 317-331. ISSN 1387-3741

Vadgama, S., Mann, J., Bashir, Z. et al. (3 more authors) (2022) Predicting survival for chimeric antigen receptor T-cell therapy: a validation of survival models using follow-up data from ZUMA-1. Value in Health, 25 (6). pp. 1010-1017. ISSN 1098-3015

Bullement, A. orcid.org/0000-0001-7091-0972 (2022) Book review: Cure models: Methods, applications and implementation. Journal of the Royal Statistical Society: Series A (Statistics in Society), 185 (2). pp. 741-742. ISSN 0964-1998

Shields, G.E., Pennington, B. orcid.org/0000-0002-1002-022X, Bullement, A. orcid.org/0000-0001-7091-0972 et al. (2 more authors) (2022) Out of date or best before? A commentary on the relevance of economic evaluations over time. PharmacoEconomics, 40 (3). pp. 249-256. ISSN 1170-7690

Bullement, A. orcid.org/0000-0001-7091-0972, Knowles, E.S., DasMahapatra, P. et al. (2 more authors) (2021) Cost-effectiveness analysis of rFVIIIFc versus contemporary rFVIII treatments for patients with severe hemophilia A without inhibitors in the United States. PharmacoEconomics - Open, 5 (4). pp. 625-633. ISSN 2509-4262

Bullement, A. orcid.org/0000-0001-7091-0972, Knowles, E., Langenfeld, M. et al. (3 more authors) (2021) An economic comparison of treatment strategies with anakinra in systemic juvenile idiopathic arthritis (sJIA). Open Access Rheumatology: Research and Reviews, 13. pp. 257-266. ISSN 1179-156X

Hatswell, A.J., Bullement, A. orcid.org/0000-0001-7091-0972, Schlichting, M. et al. (1 more author) (2021) What is the impact of the analysis method used for health state utility values on QALYs in oncology? A simulation study comparing progression-based and time-to-death approaches. Applied Health Economics and Health Policy, 19 (3). pp. 389-401. ISSN 1175-5652

Cranmer, H., Shields, G.E. and Bullement, A. orcid.org/0000-0001-7091-0972 (2020) A comparison of partitioned survival analysis and state transition multi-state modelling approaches using a case study in oncology. Journal of Medical Economics, 23 (10). pp. 1176-1185. ISSN 1369-6998

Bullement, A. orcid.org/0000-0001-7091-0972, Podkonjak, T., Robinson, M.J. et al. (4 more authors) (2020) Real-world evidence use in assessments of cancer drugs by NICE. International Journal of Technology Assessment in Health Care, 36 (4). pp. 388-394. ISSN 0266-4623

Bullement, A. orcid.org/0000-0001-7091-0972, Willis, A., Amin, A. et al. (3 more authors) (2020) Evaluation of survival extrapolation in immuno-oncology using multiple pre-planned data cuts: learnings to aid in model selection. BMC Medical Research Methodology, 20. 103. ISSN 1471-2288

Bullement, A. orcid.org/0000-0001-7091-0972, McMordie, S.T., Hatswell, A.J. et al. (2 more authors) (2020) Cost-effectiveness analysis of recombinant factor VIII Fc-fusion protein (rFVIIIFc) for the treatment of severe hemophilia A in Italy incorporating real-world dosing and joint health data. PharmacoEconomics - Open, 4. pp. 133-142. ISSN 2509-4262

Gladwell, D., Bullement, A., Cowell, W. et al. (2 more authors) (2020) "Stick or Twist?” : negotiating price and data in an era of conditional approval. Value in Health, 23 (2). pp. 191-199. ISSN 1098-3015

Bullement, A. orcid.org/0000-0001-7091-0972, Cranmer, H.L. and Shields, G.E. (2019) A review of recent decision-analytic models used to evaluate the economic value of cancer treatments. Applied Health Economics and Health Policy, 17 (6). pp. 771-780. ISSN 1175-5652

Bullement, A. orcid.org/0000-0001-7091-0972, Taylor, M., McMordie, S.T. et al. (2 more authors) (2019) NICE, in confidence : an assessment of redaction to obscure confidential information in single technology appraisals by the National Institute for Health and Care Excellence. PharmacoEconomics, 37 (11). pp. 1383-1390. ISSN 1170-7690

Bullement, A. orcid.org/0000-0001-7091-0972, Nathan, P., Willis, A. et al. (6 more authors) (2019) Cost effectiveness of Avelumab for metastatic Merkel cell carcinoma. PharmacoEconomics - Open, 3 (3). pp. 377-390. ISSN 2509-4262

Bullement, A., Latimer, N.R. orcid.org/0000-0001-5304-5585 and Bell Gorrod, H. (2019) Survival extrapolation in cancer immunotherapy: a validation-based case study. Value in Health, 22 (3). pp. 276-283. ISSN 1098-3015

Hatswell, A.J., Bullement, A., Briggs, A. et al. (2 more authors) (2018) Probabilistic sensitivity analysis in cost-effectiveness models: determining model convergence in cohort models. Pharmacoeconomics, 36 (12). pp. 1421-1426. ISSN 1170-7690

Bullement, A. orcid.org/0000-0001-7091-0972, Underhill, S., Fougeray, R. et al. (1 more author) (2018) Cost-effectiveness of trifluridine/tipiracil for previously treated metastatic colorectal cancer in England and Wales. Clinical Colorectal Cancer, 17 (1). e143-e151. ISSN 1533-0028

Gooding, S., Lau, I.-J., Sheikh, M. et al. (7 more authors) (2015) Double relapsed and/or refractory multiple myeloma : clinical outcomes and real world healthcare costs. PLoS ONE, 10 (9). e0136207.

Proceedings Paper

Bullement, A., Critchlow, S., Stevenson, M.D. orcid.org/0000-0002-3099-9877 et al. (2 more authors) (2022) HTA225 A review of external evidence used to support survival extrapolation in assessments of cancer drugs by the National Institute for Health and Care Excellence (NICE). In: Value in Health. ISPOR Europe 2022, 06-09 Nov 2022, Vienna, Austria. Elsevier BV , S340-S340.

Critchlow, S., Xiao, Y., Crabb, S. et al. (9 more authors) (2022) POSC4 Modeling health-related outcomes with avelumab as a first-line maintenance treatment following chemotherapy vs. best supportive care (BSC) for patients with locally advanced or metastatic urothelial cancer in the UK. In: Value in Health. Virtual ISPOR Europe 2021, 30 Nov - 03 Dec 2021, Virtual conference. Elsevier BV , S32-S33.

Bullement, A. orcid.org/0000-0001-7091-0972, Knowles, E., van Leeuwen-Gorter, A. et al. (4 more authors) (2020) PIH4 An economic comparison of treatment strategies with anakinra in systemic juvenile idiopathic arthritis (SJIA). In: Value in Health. Virtual ISPOR Europe 2020, 16-19 Nov 2020, Virtual conference. Elsevier BV , S539.

Metry, A., Sullivan, W., Kearns, B.C. et al. (1 more author) (2019) Would a cohort-level approach to cost-effectiveness modelling have led to a different decision in an important nice appraisal for obesity patients? In: Value in Health. ISPOR Europe 2019, 02-07 Nov 2019, Copenhagen, Denmark. Elsevier , S577-S578.

Cranmer, H., Shields, G. and Bullement, A. orcid.org/0000-0001-7091-0972 (2019) PCN103 A comparison of partitioned survival analysis and state transition modelling approaches – findings from a case study in oncology. In: Value in Health. ISPOR Europe 2019, 02-06 Nov 2019, Copenhagen, Denmark. Elsevier BV , S456-S456.

Bullement, A. orcid.org/0000-0001-7091-0972, Cranmer, H. and Shields, G. (2019) PCN106 A review of decision analytic models to evaluate the cost-effectiveness of cancer treatments : 5-years of publications and single technology appraisals. In: Value in Health. ISPOR Europe 2019, 02-06 Nov 2019, Copenhagen, Denmark. Elsevier BV , S456-S457.

Cranmer, H., Shields, G. and Bullement, A. orcid.org/0000-0001-7091-0972 (2019) PCN224 Treatment benefit discontinuation : comparison of a partitioned survival analysis and a semi-Markov multi-state model approach using an oncology case study. In: Value in Health. ISPOR Europe 2019, 02-06 Nov 2019, Copenhagen, Denmark. Elsevier BV , S479-S479.

Li, N., Bullement, A. orcid.org/0000-0001-7091-0972, McMordie, S. et al. (2 more authors) (2019) RO4 Cost-effectiveness analysis of rFVIIIFc, PEGylated rFVIII, and emicizumab for the prophylactic treatment of severe hemophilia A patients without inhibitors in the United States. In: Value in Health. ISPOR 2019: Rapid. Disruptive. Innovative: A New Era in HEOR, 18-22 May 2019, New Orleans, LA, USA. Elsevier , S389.

Hatswell, A.J., Bullement, A. orcid.org/0000-0001-7091-0972, Schlichting, M. et al. (1 more author) (2019) PCN259 Should health state utility values (HSUVS) in cancer immunotherapies (IOS) be analyzed by time to death (TTD) or progression status? Results of a simulation study. In: Value in Health. ISPOR 2019 : Rapid. Disruptive. Innovative: A New Era in HEOR, 18-22 May 2019, New Orleans, LA, USA. Elsevier BV , S105-S105.

Gosain, S., Bullement, A. orcid.org/0000-0001-7091-0972, Kirby, J. et al. (3 more authors) (2018) Comparison of pharmacoeconomic (PE) evaluations for drugs for rare diseases (DRDs) evaluated by CADTH and NICE. In: Value in Health. ISPOR Europe 2018: New Perspectives for Improving 21st Century Health Systems, 10-14 Nov 2018, Barcelona, Spain. Elsevier , S465.

Sullivan, W., Bullement, A. orcid.org/0000-0001-7091-0972 and Lee, D. (2018) Dice for NICE? Lessons from a single technology appraisal. In: Value in Health. ISPOR Europe 2018: New Perspectives for Improving 21st Century Health Systems, 10-14 Nov 2018, Barcelona, Spain. Elsevier , S379-S379.

Willis, A., Bullement, A. orcid.org/0000-0001-7091-0972 and Sullivan, W. (2018) Estimated cost savings from dose banding guidance: a case study using treatments for stage IV melanoma. In: Value in Health. ISPOR Europe 2018: New Perspectives for Improving 21st Century Health Systems, 10-14 Nov 2018, Barcelona, Spain. Elsevier , S378-S379.

Bharmal, M., Amin, A., Stapelkamp, C. et al. (5 more authors) (2018) Cost-effectiveness (CE) of avelumab vs standard care (SC) for the treatment of patients (pts) with metastatic Merkel cell carcinoma (mMCC). In: Annals of Oncology. 43rd ESMO Congress (ESMO 2018), 19-23 Oct 2018, Munich, Germany. Elsevier , p. 461.

Bullement, A. orcid.org/0000-0001-7091-0972, Amin, A., Stapelkamp, C. et al. (5 more authors) (2018) Modelling overall survival in immunotherapy using parametric techniques : Avelumab in previously treated metastatic Merkel cell carcinoma. In: Value in Health. ISPOR 21st Annual European Meeting, 10-14 Nov 2018, Barcelona, Spain. Elsevier , S11-S11.

Bullement, A. orcid.org/0000-0001-7091-0972 and Hatswell, A.J. (2018) MO2 - How errors in the implementation of background mortality leads to bias in models. In: Value in Health. ISPOR 8th Asia-Pacific Conference, 08-11 Sep 2018, Tokyo, Japan. Elsevier , S8.

Bullement, A. orcid.org/0000-0001-7091-0972, D'Angelo, S.P., Amin, A. et al. (5 more authors) (2018) Predicting overall survival in patients (pts) with treatment-naive metastatic Merkel cell carcinoma (mMCC) treated with avelumab. In: Journal of Clinical Oncology. 2018 ASCO Annual Meeting, 01-05 Jun 2018, Chicago, IL, USA. American Society of Clinical Oncology .

Mahon, S., Bullement, A. orcid.org/0000-0001-7091-0972, Willis, A. et al. (5 more authors) (2017) PCN155 - Cost effectiveness of Nivolumab for patients with advanced, previously treated renal cell carcinoma in Scotland. In: Value in Health. ISPOR 20th Annual European Congress, 04-08 Nov 2017, Glasgow, Scotland. Elsevier , A440.

Hatswell, A.J., Cooper, M., Bharmal, M. et al. (1 more author) (2017) Predicting outcomes from multiple uncontrolled historical studies of standard care – progression-free survival and overall survival in untreated metastatic Merkel cell carcinoma. In: Value in Health. ISPOR 20th Annual European Congress, 04-08 Nov 2017, Glasgow, Scotland. Elsevier , A422.

Bullement, A. orcid.org/0000-0001-7091-0972 and Critchlow, S. (2016) PRM119 - An exploration of techniques for addressing uncertainty in survival estimates used within partitioned-survival models. In: Value in Health. ISPOR 19th Annual European Congress, 29 Oct - 02 Nov 2016, Vienna, Austria. Elsevier , A378-A379.